6533b858fe1ef96bd12b6439

RESEARCH PRODUCT

Reverse remodeling and arrhythmic burden reduction in a patient with an implantable cardioverter defibrillator treated with sacubitril/valsartan: Case report

Antonino MignanoAntonino SaladinoCinzia NugaraEgle CorradoGiuseppe CoppolaGiusy MorganteGiuseppina Novo

subject

medicine.medical_specialtymedicine.medical_treatmentARNIlcsh:Medicineheart failureCase ReportheartCase Reports030204 cardiovascular system & hematologySacubitril03 medical and health sciences0302 clinical medicineInternal medicinemedicineEnalaprilVentricular remodelingReverse remodelingarrhythmic burdenremodelinglcsh:R5-920business.industrylcsh:RGeneral Medicinemedicine.diseaseImplantable cardioverter-defibrillatorfailureValsartan030220 oncology & carcinogenesisHeart failureCardiologylcsh:Medicine (General)businessSacubitril Valsartanmedicine.drug

description

Abstract Sacubitril/valsartan has been shown to reduce cardiovascular mortality and hospitalizations in patients with HFrEF when compared to enalapril. There are also some evidences of its potential antiarrhythmic effects. We present a report where we found a relation between reverse ventricular remodeling and arrhythmic reduction in a patient treated with sacubitril/valsartan.

10.1002/ccr3.2655http://europepmc.org/articles/PMC7455401